换一批
换一批Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
第一作者：
Michael B,Atkins
第一单位：
Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, E Campus, Kirstein 158, Boston, MA 02215, USA. matkins@bidmc.harvard.edu
作者：
主题词
老年人(Aged);老年人, 80以上(Aged, 80 and over);生物利用度(Biological Availability);癌, 肾细胞(Carcinoma, Renal Cell);置信区间(Confidence Intervals);剂量效应关系, 药物(Dose-Response Relationship, Drug);用药计划表(Drug Administration Schedule);女(雌)性(Female);人类(Humans);输注, 静脉内(Infusions, Intravenous);肾肿瘤(Kidney Neoplasms);男(雄)性(Male);中年人(Middle Aged);肿瘤侵润(Neoplasm Invasiveness);肿瘤分期(Neoplasm Staging);概率(Probability);预后(Prognosis);危险性评估(Risk Assessment);挽救疗法(Salvage Therapy);西罗莫司(Sirolimus);存活率分析(Survival Analysis);治疗结果(Treatment Outcome)
DOI
10.1200/JCO.2004.08.185
PMID
14990647
发布时间
2022-04-10
- 浏览107
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
